Abstract
IntroductionThe growing adoption of molecular and genomic characterization is changing the current landscape of treatment of endometrial cancer (EC) patients. Using the surrogate molecular classification EC patients are classified in...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
